MedTrace Logo

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

NCT06485271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 504

Last updated 2024-07-03

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Conditions

Interventions

DRUG

Camrelizumab

200mg,iv,d1,Q2W/Q3W

DRUG

apatinib

250mg,qd

DRUG

chemotherapy

Standard treatment

Sponsors & Collaborators

  • Changzhi People's Hospital Affiliated to Changzhi Medical College

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-10-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485271 on ClinicalTrials.gov